Presynaptic dopaminergic function in the striatum of schizophrenic patients

Schizophrenia Research

Volumn 23, Issue 2, 1997, Pages 167-174

  Dao Castellana, Marie Hélène ^a,e   Paillère Martinot, Marie Laure ^a,e   Hantraye, Philippe ^a   Attar Lévy, Dominique ^c   Rémy, Philippe ^a   Crouzel, Christian ^a   Artiges, Eric ^a   Féline, André ^b   Syrota, André ^a   Martinot, Jean Luc ^a,d,f  

^a DIF   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

^d Hopital Albert Chenevier   (France)

^e Centre P Paumelle   (France)

^f SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

18F DOPA; dopamine; PET; schizophrenia

Indexed keywords

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA;

ADOLESCENT; ADULT; CORPUS STRIATUM; DOPAMINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; RECEPTORS, PRESYNAPTIC; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 17544386853     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(96)00102-8     Document Type: Article

References (39)

1. Angrist, B., Sathananthan, G., Wilk, S. and Gershon, S. (1974) Amphetamine psychosis: behavioral and biochemical aspects. J. Psychiatry Res. 11, 13-23.
2. Calne, D.B., Langsten, J.W., Martin, W.R.W., Stoessl, A.J., Ruth, T.J., Adams M.J., Pate, B.D. and Schnitzer, M. (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 317, 246-248.
3. Creese, I., Burt, D.R. and Snyder, S.H. (1976) DA receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
4. 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors. Psychopharmacology 74, 122-124.
5. Farde, L., Wiesel, F.A., Stone-Elander, S., Halldin, C., Nordstrom, A.L., Hall, H. and Sedvall, G. (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients: a positron emission tomography study with 11C raclopride. Arch. Gen. Psychiatry 47, 213-219.
6. 18F-fluoro-L-3,4-dihydroxyphenylalanine in the primate. J. Neurochem. 48, 1077-1082.
7. Gjedde, A. (1982) Calculation of glucose phosphorylation from brain uptake of glucose analogs: a re-examination. Brain Res. Rev. 4, 237-274.
8. Gjedde, A. and Wong, D.F. (1990) Modeling neuroreceptor binding of radioligands in vivo. In: Frost, J.J. and Wagner, H.N., eds. Quantitative imaging: neuroreceptors, neurotransmitters and enzymes. Raven Press, New York, pp. 51-79.
9. Guiraud, P. (1924) Conception neurologique du syndrome catatonique. Encéphale 19, 571-579.
10. Hess, E.J., Bracha, S., Kleinman, J.E. and Creese, I. (1987) Dopamine receptors subtype imbalance in schizophrenia. Life Sci. 40, 1487-1497.
11. Hietala, J., Syvalahti, E., Vuorio, K., Nagren, K., Lehikoinen, P., Ruotsalainen, U., Rakkolainen, V., Lehtinen, V. and Wegelius, U. (1994) Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch. Gen. Psychiatry 51, 116-123.
12. Hietala, J., Syvalahti, E., Vuorio, K., Rakkolainen, V., Bergman, J., Haaparanta, M., Solin, O., Kuoppamaki, M., Kirvela, O., Ruotsalainen, U. and Salokangas, R.K.R. (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346, 1130-1131.
13. Hsiao, J.K., Colison, J., Bartko, J.J., Doran, A.R., Konicki, P.E., Potter, W.Z. and Pickar D. (1993) Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry 50, 606-614.
14. Kay, S.R., Fiszbein, A. and Ofler, L.A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261-276.
15. 3H-Spiperone binding sites in post-mortem brain from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms, J. Neural Transm. 75, 1-10.
16. Laruelle, M., Abi-Dargham, A., Van Dyck, C.H., Gil, R., D'Souza, C.D., Erdos, J., McChance, E., Rosenblatt, W., Fingado, C., Zoghbi, S.S., Baldwin, R.M., Seibyl, J.P., Kristal, J.H., Charney, D.S. and Innis, R.B. (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA. 93, 9235-9240.
17. 18F]fluorodopa uptake into human brain by amino acid demonstrated by positron emission tomography. Ann. Neurol. 20, 258-262.
18. Mangin, J.F., Frouin, V., Bloch, I., Bendriem, B. and Lopez-Krahe, J. (1994) Fast nonsupervised 3D registration of PET and MRI images of the brain. J. Cereb. Blood Flow Metab. 14, 749-762.
19. Martin, W.R.W., Palmer, M.R., Patlak, CS. and Calne, D.B. (1989) Nigrostriatal function in humans studied with positron emission tomography. Ann. Neurol. 26, 535-542.
20. 76Br-Bromospiperone in untreated schizophrenic patients. Am. J. Psychiatry 147, 44-50.
21. 76Br-Bromolisuride. Br. J. Psychiatry 158, 346-350.
22. Martinot, J.I., Paillère-Martinot, M.L., Loc'h, C., Lecrubier, Y., DaoCastellana, M.H., Aubin, F., Allilaire, J.F., Mazoyer, B., Mazière, B. and Syrota, A. (1994) Central D2 receptors and negative symptoms of schizophrenia. Br. J. Psychiatry 164, 27-34.
23. Matthysse, S. (1974) Dopamine and the pharmacology of schizophrenia: the state of the evidence. J. Psychiat. Res. 11, 107-113.
24. Mazoyer, B., Trebossen, R., Deutch, R., Casey, M. and Blohm, K. (1991) Physical characteristics of the ECAT 953B/31: a new high resolution brain positron tomograph. IEEE Trans. Med. Imaging 10, 499-504.
25. Oke, A.F., Putz, C., Adams, R.N. and Bird, E.D. (1992) Neuroleptic treatment is an unlikely cause of elevated dopamine in thalamus of schizophrenic subjects. Psychiatry Res. Neuroimaging 45, 203-208.
26. Owen, R., Owen, F., Poulter, M. and Crow, T.J. (1984) Dopamine D2 receptors in substantia nigra in schizophrenia. Science 231, 152-154.
27. Pate, B.D., Kawamata, T., Yamada, T., McGeer, E.G., Hewitt, K.A., Snow, B.J., Ruth, T.J. and Calne, D.B. (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 34, 331-338.
28. Patlak, C. S. and Blasberg, R. G. (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5, 584-590.
29. Pickar, D., Labarca, R., Linnoila, M., Roy, A., Hommer, D., Everett, D. and Paul, S.M. (1984) Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225, 954-956.
30. Pickar, D., Labarca, R., Doran, A.R., Wolkowitz, O.M., Roy, A., Breier, A., Linnoila, M. and Paul, S.M. (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch. Gen. Psychiatry 43, 669-676.
31. Pickar, D., Breier, A., Hsiao, J.K., Doran, A.R., Wolkowitz, O.M., Pato, C.N., Konicki, P.E. and Potter, W.Z. (1990) Cerebrospinal fluid and plasma metabolites and their relation to psychosis. Arch. Gen. Psychiatry 47, 641-648.
32. Reith, J., Benkelfat, C., Kuwabara, H., Chouinard, G., Etienne, P., Bachneff, S. and Gjedde, A. (1990) Cerebral dopa decarboxylase activity in schizophrenia measured by positron emission tomography. Society for Neuroscience Abstracts 1, 166.
33. Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., Dyve, S.E., Etienne, P., Evans, A.C., Lal, S., Shevell, M., Savard, G., Wong, D.F., Chouinard, G. and Gjedde, A. (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA 91, 11651-11654.
34. 18F-Fluorodopa uptake in five grafted Parkinsonian patients. Ann. Neurol. 38, 580-588.
35. Reynolds, G.P. (1989) Beyond the dopamine hypothesis: the neurochemical pathology of schizophrenia. Br J Psychiatr. 155, 305-316.
36. Rogers, D. (1990) Catatonia: a contemporary approach. Neuropsychiatric practice and opinion. J. Neuropsychiatry 3, 334-340.
37. Sawle, G.V., Playford, E.D., Burn, D.J., Cunningham, V.J. and Brooks, D.J. (1994) Separating Parkinson's disease from normality: discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch. Neurol. 51, 237-243.
38. 18F-Fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34, 324-330.
39. Wong, D.F., Wagner, H.N., Tune, L.E., Dannals, R.F., Pearlson, G.D., Links, J.M., Taminga, C.A., Brousolle, E.P., Ravert, H.V., Wilson, A.A., Thomas-Toung, J.K., Malat, J., Williams, J.A., O'Tuana, L.A., Snyder, S.H., Kuhar, M.J. and Gjedde, A. (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234, 1558-1563.